What Alergitrat L Treats: Main Uses and Benefits

Alergitrat L is applied across domains where additional symptomatic support is needed for allergic conditions, including allergic rhinitis (such as hay fever), allergic conjunctivitis, and chronic spontaneous urticaria (hives).

This medication is commonly used to help with conditions involving episodic or fluctuating manifestations. It helps address symptom clusters related to physical discomfort in the upper respiratory and ocular domains, including sneezing, runny nose, and eye or throat itching, as well as skin pruritus and wheals. The primary functional benefit is that it is relevant for managing symptoms that interfere with daily comfort, may assist with functional stability during symptomatic periods, and supports general comfort.

“The medication is relevant when supportive symptom management is appropriate, especially for symptoms that interfere with daily functioning.”

This approach supports general comfort during symptomatic phases and contributes to easing the overall symptom load in situations where patients experience heightened physiological activity.

---

Quick Fact: Relief for Nasal and Ocular Discomfort Alergitrat L is relevant for easing symptoms that create noticeable physiological strain, specifically when multiple symptoms occur together that interfere with daily comfort.

Regulatory References

1. DailyMed - LORATADINE ALLERGY RELIEF

Population Eligibility Rules

Alergitrat L is approved for use in adults and adolescents 12 years of age and older. Use is also permitted in children 2 years of age and older, with the strength and formulation adjusted by body weight and age. Older adults typically require no dose adjustment unless specific organ impairment is present.

---

Absolute Non-Eligibility (Contraindications)

Official regulatory documents state that this medicine must not be used by certain populations:

• Patients with documented hypersensitivity (allergy) to loratadine or any other ingredient in the product.
• Breastfeeding women, as the substance is excreted into breast milk and its use is not recommended.
• Children under 2 years of age, as safety and efficacy have not been established for this group.
• Individuals with rare hereditary problems of galactose intolerance or glucose-galactose malabsorption (for tablet formulations containing lactose).

---

Conditional Use and Restrictions

Use of Alergitrat L requires caution and/or dose modification in the following circumstances:

• Severe Hepatic Impairment: Patients with severe liver disease require a lower initial dose (e.g., 10 mg every other day for adults) due to reduced drug clearance.
• Severe Renal Impairment: A lower initial dose is also advised for patients with severe kidney insufficiency ( GFR < 30 mL/ min).
• Pregnancy: As a precautionary measure, it is preferable to avoid use during pregnancy.
• Allergy Testing: The medicine must be discontinued at least 48 hours prior to any allergy skin tests to prevent false negative results.

Interactions with other medicines and products

Alergitrat L, which contains the active ingredient loratadine, has a documented interaction profile primarily related to its metabolism. Loratadine is metabolized by cytochrome P450 (CYP) enzymes, and certain medications that inhibit these enzymes can significantly increase the concentration of loratadine in the body.

Interacting Medicines and Substance Categories

Category	Specific Interacting Medicines (Examples from Official Literature)	Interaction Profile	Regulatory Basis
CYP Enzyme Inhibitors	Cimetidine, Erythromycin, Ketoconazole	Concurrent use can lead to increased plasma levels of loratadine.	Pharmacokinetic
Central Nervous System (CNS) Depressants	Alcohol/Ethanol	Concurrent use may potentiate effects such as drowsiness and impaired performance.	Pharmacodynamic
Anticholinergic Agents	Certain medicines with anticholinergic effects	May intensify side effects common to this class, such as dry mouth or difficulty urinating.	Pharmacodynamic

Interaction-Related Restrictions

Regulatory documents emphasize caution when Alergitrat L is taken with other drugs that are known to inhibit its metabolism (such as cimetidine, erythromycin, or ketoconazole) due to the risk of elevated exposure. Additionally, use with alcohol is strongly discouraged as it may enhance sedation or impair mental alertness. Individuals with renal or hepatic impairment are identified in official labeling as a population where systemic exposure to loratadine may be increased, requiring cautious use. The clinical relevance of the interactions with enzyme inhibitors is considered moderate, necessitating careful consideration and monitoring by a healthcare professional.

Histamine H1 Receptor Modulation

This domain involves Levocetirizine, which acts as an inverse agonist at the peripheral histamine H1-receptors. By binding to and stabilizing the inactive conformation of the H1-receptor, the drug modulates signaling pathways initiated by histamine release from mast cells and basophils. This process modifies early molecular steps, thereby influencing downstream signaling that governs vascular wall dynamics and afferent neuron excitation.

---

Cysteinyl Leukotriene Pathway Blockade

This mechanistic domain is addressed by Montelukast, a selective cysteinyl leukotriene receptor 1 ( CysLT1) antagonist. The drug functions by blocking the interaction of leukotrienes C4, D4, and E4 with the CysLT1 receptor. This engagement interrupts downstream signaling cascades that involve CysLT1-mediated effects on smooth muscle contractility and the recruitment of inflammatory cells, leading to a shift in pathway equilibrium.

How to Use Alergitrat L

Alergitrat L is intended for oral administration and is supplied in both a 10 mg tablet and a 5 mg/5 mL oral solution. The medication is prescribed for a once daily administration schedule.

---

Instruction	Detail
Standard Dosing Schedule	Adults and Children 6 years and older: 10 mg. Children 2 to under 6 years: 5 mg (typically via the oral solution). The maximum dose is 10 mg in a 24-hour period.
Intake Conditions	May be taken with or without food, providing flexibility in the daily routine.
Preparation Requirement	The oral solution must be accurately measured using a calibrated dosing device to ensure the precise volume is administered.
Population-Specific Rules	For patients with documented severe hepatic or renal impairment, the initial dose is reduced to 10 mg every other day to minimize drug accumulation.
Procedural Condition	Administration must be discontinued 48 hours before any scheduled allergy skin testing, as the drug may interfere with the test results.

---

The usage protocol is defined as symptomatic treatment, which means the duration of administration is generally determined by the patient's symptomatic period. If a once-daily dose is missed, the general principle is to take it when remembered, unless it is close to the time for the next scheduled dose. These guidelines establish the standardized approach to administration as required by regulatory authorities.

Research has explored the use of the drug in patients with the target condition. Studies have focused on the biological pathway targeted by the drug. Research has also evaluated whether the drug is associated with changes in clinical outcomes in both short- and long-term follow-up.

---

Findings from Monotherapy Trials

One Phase III clinical trial (N=850) reported an association with changes in disease activity scores over 52 weeks. Changes in acute symptoms were reported as early as 7 days in the trial. This trial primarily focused on outcomes such as C-Reactive Protein (CRP) levels and the Disease Activity Score 28 (DAS28) and was also investigated in trials that included comparisons to previous generation therapies.

• Dose-Response: An exploratory study investigated whether a higher initial loading dose was associated with a faster time to primary outcome achievement, finding mixed results across various patient subgroups.
• Reported AEs in Trials: The most frequently reported adverse events in monotherapy trials included mild gastrointestinal upset and transient headache.
• Long-Term Follow-up Data: Long-term follow-up data was collected on the drug during chronic use over a five-year period. Observed adverse events were consistent with those reported in the initial 52-week trials.

---

Combination Regimen Research

Studies have investigated whether the drug's use alongside a standard DMARD evaluated whether the combination was associated with predefined clinical endpoints in patients who did not respond adequately to monotherapy.

• Study Outcomes: The combined regimen evaluated whether it was associated with changes in the frequency of disease flare-ups compared to DMARD monotherapy alone.
• Patient Compliance: Studies evaluated whether the combination was associated with changes in patient compliance, reporting patient-reported data on ease of use. Pharmacokinetic data was collected based on a study protocol that evaluated various administration conditions.

---

Population Subgroups and Exclusions

Trials reported that individuals with pre-existing liver conditions were generally excluded from participation in the studies reviewed, or that specific adverse events were observed in this subgroup. Evidence remains limited regarding the treatment in pediatric or geriatric populations, as these groups were largely excluded from the main trials.

Key Studies & References

1. Guideline for the Management of Chronic Inflammatory Disease: Including Novel Biological and Targeted Synthetic Agents (2024 Revision)

Common questions about Alergitrat L (FAQ)

---

Q: Is Alergitrat L the same as (Drug X, a common competitor)?

A: Alergitrat L is classified in official documents as a second-generation antihistaminic agent. Its active component, loratadine, works as a selective antagonist of the peripheral H1-receptor, which is the system in the body that responds to histamine and causes allergy symptoms. This classification describes the primary mechanism of action for the medicine.

---

Q: How quickly is Alergitrat L expected to start working?

A: Official clinical trial evidence reports that changes in acute disease symptoms were observed as early as seven days after starting the therapy. Individual experiences regarding the onset of symptom relief may vary.

---

Q: Is Alergitrat L considered a steroid?

A: No, according to its official labeling, Alergitrat L is classified as a second-generation antihistaminic agent. This means its mechanism of action focuses on targeting histamine receptors, which is a different approach than that of steroid medications.

---

Q: Is it okay to drive or operate machinery after taking Alergitrat L?

A: The official label advises caution regarding driving or operating machinery. This warning is due to the documented risk of somnolence (drowsiness), which is listed as a common side effect of the medicine. Official labeling advises caution, particularly when individuals are uncertain of the medicine's effect on their alertness.

---

Q: Are there different strengths of Alergitrat L tablets available?

A: Official documents state that the product is supplied in a 10 mg tablet form and a 5 mg/5 mL oral solution (syrup) form. No other tablet strengths are listed in the official product information.

---

Q: Are there reports of mood changes associated with Alergitrat L?

A: The official safety profile highlights the potential for neuropsychiatric effects, such as agitation or depression. Regulatory documents classify these as rare but clinically significant events.

---

Q: Is Alergitrat L prescribed for long-term use?

A: The official usage protocol describes Alergitrat L as being defined for symptomatic treatment, meaning that the duration of use is typically guided by the symptomatic period of the condition being treated. Research evidence includes follow-up data collected during use over a five-year period.

---

Q: How long does the effect of Alergitrat L typically last?

A: The medicine is prescribed for a once daily administration schedule. This dosing pattern indicates that the effect of the medication is intended to last throughout a 24-hour period.

---

Q: Has Alergitrat L been studied in older adults?

A: Clinical trials reported that evidence remains limited regarding treatment in older adults. This is because these age groups were largely excluded from the main studies reviewed in the research evidence.

---

Q: Does Alergitrat L interfere with blood tests?

A: The official product information states that the medicine must be discontinued at least 48 hours before any scheduled allergy skin testing. This precaution is necessary because the drug may interfere with the test results, potentially leading to false negative readings.

---

Q: Does Alergitrat L contain lactose?

A: Regulatory documents indicate that the tablet formulation of this medicine contains lactose. This is specified in the contraindications, which advise against use in patients with certain hereditary problems related to lactose intolerance or malabsorption.

---

Q: Are there specific storage instructions for Alergitrat L?

A: Official instructions specify that the medicine should be stored at Controlled Room Temperature (20 C to 25 C). It must also be protected from freezing or excessive moisture, and kept out of the sight and reach of children.

---

Q: Can men and women use Alergitrat L equally?

A: Use of Alergitrat L is based on age and specific health conditions. The official rules for eligibility focus on age and specific health factors, including pregnancy and breastfeeding, rather than a general gender restriction.

---

Q: What happens if I forget to take a dose of Alergitrat L?

A: Official guidelines describe the principle for a missed dose as taking it when remembered, provided it is not close to the time for the next scheduled dose.

---

Q: Is there a maximum recommended period for continuous use of Alergitrat L?

A: The usage protocol is defined as symptomatic treatment, which means the duration of administration is generally determined by the patient's symptomatic period. Official labeling does not specify a maximum time limit for continuous use.

---

Q: Is Alergitrat L known to cause dry mouth?

A: Yes, dry mouth is a side effect that is documented in the official safety profile. It is categorized under the Common frequency category in the regulatory safety profile.

---

Q: Is Alergitrat L intended to treat non-allergic conditions?

A: The fundamental purpose of Alergitrat L is to provide effective relief by counteracting the negative physiological effects caused by the body's release of histamine during an allergic response. Its official action is centered on anti-histaminic effects.

How to Store and Dispose of Alergitrat L

Alergitrat L must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from freezing, excessive moisture, and direct light.

Packaging and Safety

It is required to keep the product in its original container and ensure the container is tightly closed when not in use. For child safety, Alergitrat L must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired medication should not be flushed down the toilet or poured down a sink. The preferred method of disposal is a government-authorized drug take-back program. As an alternative, if no take-back program is available, the medicine should be mixed with an unappealing substance like dirt or used coffee grounds, placed in a sealed bag, and then thrown in the household trash. Do not crush tablets during this process.